Cellares has partnered with the University of Wisconsin School of Medicine and Public Health to automate the production of a CRISPR-edited GD2 CAR-T investigational therapy.
The collaboration aims to address manufacturing bottlenecks in cell therapy and advance the development of novel treatments for solid tumours towards clinical trials.
Cellares’ Cell Shuttle technology provides an integrated, automated solution for early-phase biotechnology and academic cell therapy developers.
It enables economies of scale and reduces batch prices by up to 50% compared to conventional contract development and manufacturing organisations.
The platform ensures a smooth transition from clinical development to commercial-scale manufacturing, eliminating costly process redesigns and technology transfers.
Cellares co-founder and CEO Fabian Gerlinghaus said: “Solid tumors can be challenging to treat, and many patients have limited therapeutic options.
“By collaborating with researchers at the University of Wisconsin–Madison on their CRISPR-edited GD2 CAR-T product, we remove the manufacturing barriers that can hinder promising research.
“Our Cell Shuttle automates and scales production to a clinical level, which accelerates the transition from academic innovation to investigational therapy and brings hope to those who need new treatment options.”
Cellares said the partnership supports its commitment to providing researchers with an automated, scalable manufacturing platform from the early stages of development.
Cell Shuttle allows the manufacturing of multiple cell therapy products simultaneously, addressing capacity limitations and advancing the journey from lab to clinical trials.
It automates several key developmental steps, which significantly speeds up the advancement of life-saving therapies.
Through the clinical-scale manufacturing of the CRISPR-edited GD2 CAR-T project, the collaboration aims to draw potential investment and expedite the path to initial human trials.
